Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Recruiting · Phase 2 · NCT05854498
Conditions: Metastatic Colorectal Cancer
At a glance
- Research payments reported, 2025
- $758,480
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- University of Wisconsin, Madison (with Ipsen)
- Tested
- Liposomal irinotecan (drug), TAS102 (drug), Bevacizumab (drug)
- Dates
- Started 2023-10-13; completion 2028-12
- Results posted
- Not yet
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.
From ClinicalTrials.gov, last updated 2026-09-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $758,480 in research payments for this study in 2025 (6 payments).
Products named: Onivyde
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Wisconsin $758,480
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.